The emerging role of Bruton's tyrosine kinase inhibition in urticaria management.

IF 3.1 3区医学 Q2 PHARMACOLOGY & PHARMACY Expert Opinion on Drug Safety Pub Date : 2025-05-01 Epub Date: 2025-01-29 DOI:10.1080/14740338.2025.2460453

Giuseppe Lauletta, Luca Potestio, Cataldo Patruno, Mariateresa Cantelli, Maddalena Napolitano

{"title":"The emerging role of Bruton's tyrosine kinase inhibition in urticaria management.","authors":"Giuseppe Lauletta, Luca Potestio, Cataldo Patruno, Mariateresa Cantelli, Maddalena Napolitano","doi":"10.1080/14740338.2025.2460453","DOIUrl":null,"url":null,"abstract":"Introduction: Bruton's tyrosine kinase (BTK) is a cytoplasmic signaling protein expressed across a variety of immune cells, terminally differentiated plasma cells, and natural killer cells. Due to the signal potential and targetable nature of BTK, the use of BTK inhibitors (BTKis) has been proposed for the management of several diseases. Currently, the use of BTKis is under investigations for several dermatological conditions such as pemphigus, systemic lupus erythematosus, hidradenitis suppurativa, atopic dermatitis, and chronic spontaneous urticaria (CSU).Areas covered: The aim of this review is to delve into the use of BTKis in the management of CSU, in order to explore the potential of therapeutic inhibition of BTK in patients with CSU. A thorough analysis of the existing medical literature was conducted across the PubMed, Ovid, Scopus, Embase, and Cochrane Library databases up to 17 August 2024.Expert opinion: BTK use may represent a breakthrough in the management of CSU. Indeed, their use is characterized by oral administration and a favorable mechanism of action that acts on a significant pathogenic pathway rather than a single molecule. However, long-term studies are needed to further investigate safety data, although data from registered trials appear to be reassuring.","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"507-512"},"PeriodicalIF":3.1000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14740338.2025.2460453","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Bruton's tyrosine kinase (BTK) is a cytoplasmic signaling protein expressed across a variety of immune cells, terminally differentiated plasma cells, and natural killer cells. Due to the signal potential and targetable nature of BTK, the use of BTK inhibitors (BTKis) has been proposed for the management of several diseases. Currently, the use of BTKis is under investigations for several dermatological conditions such as pemphigus, systemic lupus erythematosus, hidradenitis suppurativa, atopic dermatitis, and chronic spontaneous urticaria (CSU).

Areas covered: The aim of this review is to delve into the use of BTKis in the management of CSU, in order to explore the potential of therapeutic inhibition of BTK in patients with CSU. A thorough analysis of the existing medical literature was conducted across the PubMed, Ovid, Scopus, Embase, and Cochrane Library databases up to 17 August 2024.

Expert opinion: BTK use may represent a breakthrough in the management of CSU. Indeed, their use is characterized by oral administration and a favorable mechanism of action that acts on a significant pathogenic pathway rather than a single molecule. However, long-term studies are needed to further investigate safety data, although data from registered trials appear to be reassuring.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

布鲁顿酪氨酸激酶抑制在荨麻疹治疗中的新作用。

布鲁顿酪氨酸激酶（Bruton’s tyrosine kinase， BTK）是一种细胞质信号蛋白，在多种免疫细胞、终末分化浆细胞和自然杀伤细胞中表达。由于BTK的信号潜力和靶向性，BTK抑制剂（BTKis）已被提议用于几种疾病的治疗。目前，BTKis正在研究用于几种皮肤病，如天疱疮、系统性红斑狼疮、化脓性汗腺炎、特应性皮炎和慢性自发性荨麻疹（CSU）。涵盖领域：本综述的目的是深入研究BTK在CSU治疗中的应用，以探索抑制BTK在CSU患者中的治疗潜力。到2024年8月17日，对PubMed、Ovid、Scopus、Embase和Cochrane图书馆数据库中的现有医学文献进行了全面分析。专家意见：BTK的使用可能是CSU治疗的一个突破。事实上，它们的使用特点是口服给药和有利的作用机制，作用于一个重要的致病途径，而不是单一分子。然而，需要长期研究来进一步调查安全性数据，尽管注册试验的数据似乎令人放心。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Opinion on Drug Safety 医学-药学

CiteScore

5.90

自引率

3.20%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Drug Safety ranks #62 of 216 in the Pharmacology & Pharmacy category in the 2008 ISI Journal Citation Reports. Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development.